Centrexion steps back from IPO amid volatile market

A decision by pain company Centrexion Therapeutics Corp. (Boston, Mass.) to not move forward with its NASDAQ IPO comes as market volatility has increased and several biotechs have failed to hit their desired valuations.

In the past month, at least six biotechs have gone public with lower valuations than they would have received at the midpoint of their proposed range...